Nxera Pharma to Get $10M from AbbVie for Neuro Project

Nxera Pharma Co., Ltd. has announced the achievement of a significant second R&D milestone under its multi-target discovery collaboration with AbbVie, focused on neurological diseases. This milestone triggers a milestone payment of US$10 million to Nxera.

The collaboration, launched in 2022, leverages Nxera’s proprietary NxWave™ platform to discover novel therapies targeting G protein-coupled receptors (GPCRs) associated with neurological conditions. The current milestone corresponds to the identification of validated and differentiated ‘hit’ molecules against a neurology target.

Under the terms of the agreement, Nxera is eligible to receive up to US$40 million in near-term research milestones, alongside potential option, development, and commercial milestones totaling up to US$1.2 billion, in addition to tiered royalties on global sales. This marks the second milestone achieved in the collaboration, following the first in June 2024.

Also Read: FerroptoCure Inc Concludes Series A Round

The milestone payment will be recorded in Nxera Pharma’s financial results for the third quarter of 2025.